Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults

NCT01997632 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Poliomyelitis

Interventions

BIOLOGICAL: a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)
BIOLOGICAL: a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).

Sponsor

University Hospital, Ghent